 Sangamo Therapeutics Inc SGMO announced updated preliminary results from the Phase 12 STAAR study of isaralgagene civaparvovec ST-920, Fabry disease gene therapy candidate. Get the Inside Access Traders Are Using to Profit More and Win Bigger. 